Vaxcyte Inc. Common Stock vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.4 (market cap $3.38B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 3.1× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is more actively traded (308,295 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 66 Days on average.
| PCVX | SPUS | |
|---|---|---|
Market Cap | $10.51B | $3.38B |
Volume | 2,644,694 | 308,295 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.82 | $61.15 |
52-Week Low | $40.32 | $46.65 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPUS trades at $60.53, showing minimal daily movement with a slight decline of 0.07%. Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains regular dividend distributions, with recent payments of $0.03 per share. Short interest saw significant growth in September, increasing 174.5% to 257,142 shares as of September 15, 2026.
The ETF's technical strength supports near-term upside potential, though elevated short interest indicates some bearish sentiment. Dividend consistency provides income appeal, but investors should monitor the growing short position which could increase volatility. The neutral oscillator readings suggest potential consolidation before further directional movement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →